|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2010-10-27
|
|
pubmed:abstractText |
The combination of chemotherapy with the vascular endothelial growth factor (VEGF) antibody bevacizumab is a standard of care in advanced colorectal cancer (CRC). However, biomarkers predicting outcome of bevacizumab-containing treatment are lacking. As angiopoietin-2 (Ang-2) is a key regulator of vascular remodelling in concert with VEGF, we investigated its role as a biomarker in metastatic CRC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
pubmed-author:AugustinH GHG,
pubmed-author:CoutelleOO,
pubmed-author:CremerBB,
pubmed-author:GoedeVV,
pubmed-author:HackerU TUT,
pubmed-author:HallekMM,
pubmed-author:KashkarHH,
pubmed-author:KoslowskyT CTC,
pubmed-author:NeuneierJJ,
pubmed-author:OdenthalMM,
pubmed-author:Reinacher-SchickAA,
pubmed-author:SchmiegelWW,
pubmed-author:SchnellRR,
pubmed-author:WeihrauchM RMR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
26
|
|
pubmed:volume |
103
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1407-14
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20924372-Aged,
pubmed-meshheading:20924372-Aged, 80 and over,
pubmed-meshheading:20924372-Angiopoietin-2,
pubmed-meshheading:20924372-Animals,
pubmed-meshheading:20924372-Antibodies, Monoclonal,
pubmed-meshheading:20924372-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20924372-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20924372-Colorectal Neoplasms,
pubmed-meshheading:20924372-Female,
pubmed-meshheading:20924372-Humans,
pubmed-meshheading:20924372-Male,
pubmed-meshheading:20924372-Mice,
pubmed-meshheading:20924372-Mice, Nude,
pubmed-meshheading:20924372-Middle Aged,
pubmed-meshheading:20924372-Prognosis,
pubmed-meshheading:20924372-Treatment Outcome,
pubmed-meshheading:20924372-Tumor Markers, Biological,
pubmed-meshheading:20924372-Vascular Endothelial Growth Factor A,
pubmed-meshheading:20924372-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.
|
|
pubmed:affiliation |
Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Straße 62, Cologne 50924, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies
|
